HUP0900417A3 - Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them - Google Patents

Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them

Info

Publication number
HUP0900417A3
HUP0900417A3 HU0900417A HUP0900417A HUP0900417A3 HU P0900417 A3 HUP0900417 A3 HU P0900417A3 HU 0900417 A HU0900417 A HU 0900417A HU P0900417 A HUP0900417 A HU P0900417A HU P0900417 A3 HUP0900417 A3 HU P0900417A3
Authority
HU
Hungary
Prior art keywords
polymorphs
production
pharmaceutical compositions
compositions containing
donepezil hydrochloride
Prior art date
Application number
HU0900417A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Eisai R & D Man Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15404413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0900417(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R & D Man Co filed Critical Eisai R & D Man Co
Priority claimed from PCT/JP1997/001932 external-priority patent/WO1997046527A1/en
Publication of HU0900417D0 publication Critical patent/HU0900417D0/hu
Publication of HUP0900417A3 publication Critical patent/HUP0900417A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
HU0900417A 1996-06-07 1997-06-06 Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them HUP0900417A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14629396 1996-06-07
PCT/JP1997/001932 WO1997046527A1 (en) 1996-06-07 1997-06-06 Polymorphs of donepezil hydrochloride and process for production

Publications (2)

Publication Number Publication Date
HU0900417D0 HU0900417D0 (en) 2009-08-28
HUP0900417A3 true HUP0900417A3 (en) 2012-12-28

Family

ID=15404413

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0900417A HUP0900417A3 (en) 1996-06-07 1997-06-06 Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them

Country Status (16)

Country Link
US (1) US6140321A (enExample)
JP (2) JP2005015486A (enExample)
KR (1) KR100545851B1 (enExample)
CN (1) CN1312129C (enExample)
AT (1) ATE445603T1 (enExample)
AU (1) AU1153097A (enExample)
CA (1) CA2516108C (enExample)
DE (1) DE69739622D1 (enExample)
DK (1) DK1211243T3 (enExample)
ES (1) ES2330997T3 (enExample)
HU (1) HUP0900417A3 (enExample)
PT (1) PT1211243E (enExample)
SI (1) SI22888B (enExample)
UA (1) UA60307C2 (enExample)
WO (1) WO1997046526A1 (enExample)
ZA (1) ZA975064B (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741782B2 (en) * 1997-08-21 2001-12-06 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of Alzheimer's disease
JP2001517617A (ja) * 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
DK1140090T3 (da) 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
KR100694682B1 (ko) 1999-03-03 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 4-치환 피페리딘 유도체 불화물
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
DK1311272T3 (da) 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
US20040034057A1 (en) * 2000-09-25 2004-02-19 Akio Imai Process for producing multiform crystal of donepezil hydrochloride
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
WO2003066100A1 (fr) * 2002-02-07 2003-08-14 Eisai Co., Ltd. Stimulants de la pousse de cheveux, preparations percutanees et procede de stimulation de la pousse de cheveux
ATE429452T1 (de) * 2002-05-01 2009-05-15 San Ei Gen Ffi Inc Verfahren zur modifizierung von gummi arabicum
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
WO2004099142A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
WO2006015338A2 (en) * 2004-07-30 2006-02-09 Dr. Reddy's Laboratories Ltd. Crystalline form of donepezil hydrochloride
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
AU2005288521A1 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
US8877933B2 (en) * 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
RS51271B (sr) * 2004-10-19 2010-12-31 Krka Tovarna Zdravil D.D. Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE602005016009D1 (de) * 2004-11-23 2009-09-24 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure-derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US20060122226A1 (en) * 2004-12-08 2006-06-08 Itai Adin Crystalline forms of Donepezil base
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
PL1871368T3 (pl) * 2005-04-04 2011-12-30 Eisai R&D Man Co Ltd Związki dihydropirydynowe do zastosowania w chorobach neurodegeneracyjnych i demencji
JP2009502917A (ja) * 2005-07-28 2009-01-29 テイコク ファーマ ユーエスエー インコーポレーテッド ゲル化ドネペジル組成物および該組成物の製法並びに使用法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7274339B2 (en) * 2005-09-16 2007-09-25 Smartant Telecom Co., Ltd. Dual-band multi-mode array antenna
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008117123A2 (en) * 2006-10-16 2008-10-02 Medichem, S.A. Process for preparing donepezil hydrochloride polymorphic form i
KR20090087009A (ko) 2006-10-27 2009-08-14 메디베이션 뉴롤로지 인코퍼레이티드 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
EP2081902A1 (en) * 2006-11-09 2009-07-29 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US20100113533A1 (en) * 2006-11-14 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
WO2009084030A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd. Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5488956B2 (ja) * 2008-11-25 2014-05-14 株式会社Ｄｎｐファインケミカル宇都宮 （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩のＩ形結晶とＩＩ形結晶の混晶の製造法
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
WO2011061591A1 (en) 2009-11-18 2011-05-26 Jubilant Life Sciences Limited Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
BR112012025264A2 (pt) * 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2012053016A1 (en) 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103012247B (zh) * 2013-01-18 2014-12-10 浙江东亚药业有限公司 一种盐酸多奈哌齐无水i晶型的制备方法
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
CN106397306B (zh) * 2016-10-20 2019-03-08 山东罗欣药业集团股份有限公司 一种盐酸多奈哌齐晶型化合物及其制备方法
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
EP4238555A3 (en) 2019-05-31 2023-09-20 Tecnimede, Sociedade Técnico-Medicinal, SA Immediate release fixed-dose combination of memantine and donepezil
CN120548168A (zh) 2022-12-28 2025-08-26 考里安有限责任公司 制备透皮递送系统的预混合方法
WO2024145319A1 (en) 2022-12-28 2024-07-04 Corium, Llc Method of preparing transdermal delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi

Also Published As

Publication number Publication date
SI22888A (sl) 2010-04-30
PT1211243E (pt) 2009-11-06
CA2516108A1 (en) 1997-12-11
JP2005015486A (ja) 2005-01-20
JP2009040783A (ja) 2009-02-26
CN1312129C (zh) 2007-04-25
ATE445603T1 (de) 2009-10-15
ZA975064B (en) 1998-04-01
CN1699343A (zh) 2005-11-23
UA60307C2 (uk) 2003-10-15
DK1211243T3 (da) 2010-02-08
KR20040104707A (ko) 2004-12-10
KR100545851B1 (ko) 2006-01-24
ES2330997T3 (es) 2009-12-18
DE69739622D1 (de) 2009-11-26
HK1080078A1 (en) 2006-04-21
SI22888B (sl) 2010-06-30
WO1997046526A1 (en) 1997-12-11
AU1153097A (en) 1998-01-05
HU0900417D0 (en) 2009-08-28
US6140321A (en) 2000-10-31
CA2516108C (en) 2008-12-02

Similar Documents

Publication Publication Date Title
HUP0900417A3 (en) Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them
HUP0000323A3 (en) N-substituted 2-cyanopyrrolidine derivatives, process for producing them and pharmaceutical compositions containing them
HU9603484D0 (en) Pharmaceutical compositions and process for producing symptom-transduction
IL134871A (en) Polymeric derivatives of camptothecins, process for producing such derivatives and pharmaceutical compositions containing them
IL125809A (en) Process and intermediates for production of donepezil and related compounds
HUP9603112A3 (en) New pharmaceutical formulation and process for its production
HUT73850A (en) 4-aza-androstenone derivative, pharmaceutical composition containing it, process for their production and intermediates
IL116486A0 (en) Novel piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
HUP9603428A2 (en) Novel crystalmodification of cdch and process for producing it and pharmaceutical composition containing it
HUP0000088A3 (en) N-substituted azaheterocyclic compounds, process for producing them and pharmaceutical compositions containing them
SI0770687T1 (en) Process for the preparation of nicotinic acid amide
HUP9801913A3 (en) Process for the preparation of lercanidipine hydrochloride
GB2304714B (en) New piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
EG22344A (en) Process for preparing of novel pharmaceutical composition
HUT76641A (en) Anti-helicobacter heterocyclic derivatives of azolones, pharmaceutical compositions containing them and process for producing them
HUP9600321A1 (en) Process for preparation of n-substituted cyclic-imide-derivatives
PL312693A1 (en) Oxathiolanes, method of their production and pharmaceutical compounds containing them
HUP0003823A3 (en) Cyanoguanidines process for producing them and pharmaceutical compositions containing them
HUT72019A (en) Process for preparation of 3-amino-pyridines from nitropyridines
HUP0103134A3 (en) Process for preparation crystalline forms of osanetant and pharmaceutical compositions containing them
ZA966154B (en) Aminophenylphosphonic acid compounds process for preparing them and pharmaceutical compositions containing them
ZA963350B (en) Cycloheaxane compounds process for their preparation and pharmaceutical compositions containing them
HUP0002270A3 (en) Polymorphs of donepezil hydrochloride and process for production and pharmaceutical compositions containing them
EG20289A (en) Process for preparing of novel pharmaceutical compositions comprising 3- substituted 2-oxindole -1- corboximides
IL136590A0 (en) Process for preparation of paroxetine hydrochloride

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees